In Brief: St. Jude
This article was originally published in The Gray Sheet
Executive Summary
St. Jude: Firm's cardiac rhythm management business, Pacesetter Inc., announces first implant of Regency SR+ single-chamber pacemaker in a patient at the University Hospital, Lund, Sweden. St. Jude says the device, which weighs 18.5 grams, includes sensor-driven rate control, enhanced diagnostics, and the firm's AutoCapture feature, a proprietary algorithm that enables the pacemaker to monitor the patient's heartbeat and automatically supply energy to stimulate the heart. A portable battery-operated programmer, Pacesetter's APS MICRO, accompanies the device. Recently introduced in Europe, the pocket-size programmer includes an infrared, wireless base station containing an onboard printer...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.